Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.
about
Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adultsAngiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertensionAngiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney diseasePerioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing surgery-related mortality and morbidityNephrotic syndrome in adultsOn the occasion of world kidney day 2016; work together to better protect the kidneyAntihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone systemTherapeutic modalities in diabetic nephropathy: standard and emerging approaches.The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapyHow evidence-based are the recommendations in evidence-based guidelines?The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease.Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats.Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials.The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.MYH-9 Related Platelet Disorders: Strategies for Management and DiagnosisAdditive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.The HALT polycystic kidney disease trials: design and implementation.Blood pressure and diabetic nephropathyAddressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.Renal failure (chronic)Combination therapy in hypertension: An update.The relationship of ethnicity to the prevalence and management of hypertension and associated chronic kidney disease.Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current statusEfficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial.Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment.Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.Comparative efficacy and safety of triple therapy (ramipril, telmisartan, hydrochlorothiazide) vs dual anti hypertensive therapy (ramipril or telmisartan, hydrochlorothiazide) in stage 2 hypertensive patientsCombination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis.Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland.Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset.Slowing nephropathy progression: focus on proteinuria reduction.ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease.Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure.
P2860
Q24186372-1D0A4EAD-3FE1-4A8E-B597-540C8A668AC3Q24194304-A26481F8-4EB4-4DEC-8CFB-B72B4D56FE13Q24235834-F076422A-FEE5-4FEA-9609-9EA6046F7E7BQ24235838-A3275E8C-6281-4AFA-892A-5603324859B5Q24650808-80A9B7E5-4B9C-4B5D-A88F-E384FC8DF933Q26751527-E15BBE87-6D86-426F-8C3F-C6A00954994FQ26865691-D2EB0950-9BE2-4933-94C5-CE942E6A1F5CQ27007027-96DAD5A5-EDB7-4115-B700-C4A089C3C5FEQ28211654-13354E81-6A7E-4C32-90D7-D0E1530823A8Q28469272-FCF2B943-B678-48BB-B43D-75C1EE45521FQ30340930-3A24515C-5210-4C38-948F-8E4FE0F96EBFQ30439297-025912D5-C7D8-4052-978B-CD47A7C969FEQ30664624-55AE4347-C6F5-46CF-9C15-2B36CF95D62CQ33325660-A18447BD-7B71-4C2A-9E16-F16DD5109B90Q33393007-0C6C117A-E92D-49BC-914C-C5302301B5D4Q33404886-5FC1CED8-C988-481C-AAA6-C12952C70762Q33571347-6C89D3C9-D2A3-4FAE-A339-9DAC4E72FBF5Q33683851-24C7EF6E-47A3-4478-9CC9-6C0B0B579FACQ33783689-89962857-43B0-40A6-A8C9-13668265656EQ33836604-4588BDE8-B904-418E-8085-B035C3AC789AQ33910618-B74373D4-F686-4BD4-A5F8-CE820A58A0E9Q33980931-1888BB51-B2C9-4732-9740-EB00FD42974DQ34012316-38D16951-344F-48B6-9D5E-DA3F53246D1CQ34076439-5BCBDF77-82BE-4A0F-8495-4902D79E55FDQ34124779-D5C01F97-A994-43F3-9C67-203F183EE122Q34141784-32143609-0759-4EEA-B5EB-A9BB3AC014FBQ34194508-83585AF8-437F-4DCE-ADCB-35506AD75005Q34245670-A862D03C-D36A-473A-86A1-A256AC5F439FQ34299778-709B09CB-7C2B-4601-AA2D-7913751EF0CEQ34310686-7EE47805-480F-4CAF-9B92-459EA6A57D39Q34418531-AC4CF9C8-8E7F-41D5-A94F-83EC30DCF7DEQ34604473-E6D132DD-463F-4F31-A9B3-60CA2C55BF1EQ34609043-0AA72ABD-680F-4365-A4DC-31361E0F8D9EQ34658876-3BE027FB-7895-41F6-A7ED-575121640E2BQ34774598-4E89EC47-671E-438E-ACE6-E4BAC6C54A76Q35025425-18816B01-605E-4EBC-B1AD-E35330646CA4Q35153298-1E480773-C035-426D-87DC-62F86DDBA288Q35154543-291685E6-32FE-4FB8-8A43-0BAD5D6CF2D2Q35164724-B8D46F9F-7A74-4665-98D2-512600B88ED3Q35203814-0796EF25-507A-4258-B12F-EFE36A30EDB5
P2860
Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Combination treatment of angio ...... a randomised controlled trial.
@en
Combination treatment of angio ...... in non-diabetic renal disease
@nl
type
label
Combination treatment of angio ...... a randomised controlled trial.
@en
Combination treatment of angio ...... in non-diabetic renal disease
@nl
prefLabel
Combination treatment of angio ...... a randomised controlled trial.
@en
Combination treatment of angio ...... in non-diabetic renal disease
@nl
P2093
P1433
P1476
Combination treatment of angio ...... a randomised controlled trial.
@en
P2093
Ashio Yoshimura
Hiroyuki Morita
Masyuki Takada
Naoyuki Nakao
Terukuni Ideura
Tsuguo Kayano
P304
P356
10.1016/S0140-6736(03)12229-5
P407
P577
2003-01-01T00:00:00Z